EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance

Ivo I de Vos, Daan Nieboer, Mark Frydenberg, Christian P Pavlovich, Mieke van Hemelrijck, Lui Shiong Lee, Antti Rannikko, Anders Bjartell, Axel Semjonow, Ewout W Steyerberg, Monique J Roobol

JAMA Network Open · 16.01.2025 · 8 (1) · e2454366

DOI: 10.1001/jamanetworkopen.2024.54366 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 16.01.2025. Verfasst von Ivo I de Vos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Active surveillance (AS) for patients with prostate cancer (PC) often includes fixed repeat prostate biopsies that do not account for the varying risk of reclassification to significant disease. Given the invasive nature and potential complications of biopsies, a personalized approach is needed to balance the burden of biopsies with the risk of missing disease progression.

Objective

To develop and externally validate a dynamic model that predicts an individual’s risk of PC reclassification during AS. Design, Setting, and Participants This prognostic study developed a dynamic prediction model using data from the Prostate Cancer Research International: Active Surveillance (PRIAS) study, which was initiated in 2006. Follow-up was truncated until April 2023. External validation was conducted using cohorts from the world’s largest centralized AS database, the Global Action Plan Prostate Cancer Active Surveillance initiative database. The PRIAS study is a multicenter, prospective, web-based cohort study monitoring patients undergoing AS, involving more than 175 academic, nonacademic, and private centers across 23 countries worldwide. For the development and external validation of the model, all patients diagnosed with Grade Group 1 PC who underwent at least 1 baseline or follow-up magnetic resonance imaging (MRI) and 1 follow-up biopsy were included. Data were analyzed from September 2023 to January 2024. Exposures AS, including prostate-specific antigen (PSA) tests, MRI, and prostate biopsies according to a fixed follow-up schedule. Main Outcomes and Measures A joint model for longitudinal and time-to-event data was used to predict reclassification to Grade Group 2 or greater on repeat biopsy using predefined baseline and repeated clinical characteristics. Performance was assessed using time-dependent area under the receiver operating characteristic curve and negative predictive value.

Results

The development cohort included 2512 patients (median [IQR] age, 65 [59-69] years). Characteristics significantly associated with a higher risk of reclassification were increased age, higher PSA and velocity, lower prostate volume, a suspicious lesion on MRI, and no previous negative biopsy findings. Depending on the threshold and time point used, the model demonstrated a negative predictive value of 86% to 97%. External validation included 3199 patients from 9 other cohorts. The time-dependent area under the curve ranged from 0.81 to 0.84 in the development cohort and 0.52 to 0.90 at external validation. Conclusions and Relevance In this prognostic study, the developed dynamic risk model effectively identified patients at low risk of PC reclassification during AS. After prospective validation, this model may support personalized, risk-based AS and reduce the burden of unnecessary biopsies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsWatchful WaitingHumansMaleBiopsyMiddle AgedAgedProspective StudiesProstateProstate-Specific AntigenPrognosisPrecision MedicineRisk AssessmentDisease ProgressionTime Factors

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Cabrini Institute, Cabrini Health, Monash University, Sydney, Australia.
  • The James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland.
  • King's College London, London, United Kingdom.
  • Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Sengkang General Hospital, Singapore.

Zitieren

APA

de Vos, I. I., Nieboer, D., Frydenberg, M., Pavlovich, C. P., van Hemelrijck, M., Lee, L. S., Rannikko, A., Bjartell, A., Semjonow, A., Steyerberg, E. W., & Roobol, M. J. (2025). Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance. JAMA Network Open, 8(1), e2454366. https://doi.org/10.1001/jamanetworkopen.2024.54366

Vancouver

de Vos II, Nieboer D, Frydenberg M, Pavlovich CP, van Hemelrijck M, Lee LS, et al. Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance. JAMA Network Open. 2025;8(1):e2454366. doi:10.1001/jamanetworkopen.2024.54366

BibTeX
@article{deVos2025,
  author = {de Vos, Ivo I and Nieboer, Daan and Frydenberg, Mark and Pavlovich, Christian P and van Hemelrijck, Mieke and Lee, Lui Shiong and Rannikko, Antti and Bjartell, Anders and Semjonow, Axel and Steyerberg, Ewout W and Roobol, Monique J},
  title = {Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {1},
  pages = {e2454366},
  doi = {10.1001/jamanetworkopen.2024.54366}
}
Kostenlos starten →